FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / BMC Vet Res / Restoring pars intermedia dopamine concentrations and tyrosi...
BMC veterinary research2020; 16(1); 356; doi: 10.1186/s12917-020-02565-3

Restoring pars intermedia dopamine concentrations and tyrosine hydroxylase expression levels with pergolide: evidence from horses with pituitary pars intermedia dysfunction.

Abstract: Pituitary pars intermedia dysfunction (PPID) develops slowly in aged horses as degeneration of hypothalamic dopaminergic neurons leads to proliferation of pars intermedia (PI) melanotropes through hyperplasia and adenoma formation. Dopamine (DA) concentrations and tyrosine hydroxylase (TH) immunoreactivity are markedly reduced in PI tissue of PPID-affected equids and treatment with the DA receptor agonist pergolide results in notable clinical improvement. Thus, we hypothesized that pergolide treatment of PPID-affected horses would result in greater DA and TH levels in PI tissue collected from PPID-affected horses versus untreated PPID-affected horses. To test this hypothesis, pituitary glands were removed from 18 horses: four untreated PPID-affected horses, four aged and four young horses without signs of PPID, and six PPID-affected horses that had been treated with pergolide at 2 µg/kg orally once daily for 6 months. DA concentrations and TH expression levels in PI tissues were determined by high performance liquid chromatography with electrochemical detection and Western blot analyses, respectively. Results: DA and TH levels were lowest in PI collected from untreated PPID-affected horses while levels in the pergolide treated horses were similar to those of aged horses without signs of PPID. Conclusions: These findings provide evidence of restoration of DA and TH levels following treatment with pergolide. Equine PPID is a potential animal model of dopaminergic neurodegeneration, which could provide insight into human neurodegenerative diseases.
Get Full Text
Publication Date: 2020-09-25 PubMed ID: 32977825PubMed Central: PMC7517620DOI: 10.1186/s12917-020-02565-3Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research article explores the effectiveness of pergolide treatment in restoring dopamine concentrations and tyrosine hydroxylase expression levels in horses with Pituitary Pars Intermedia Dysfunction (PPID), potentially offering insights for human neurodegenerative diseases.

Background

  • The authors of this research studied PPID, a condition that typically affects older horses.
  • PPID is characterized by the degeneration of hypothalamic dopaminergic neurons, which causes the proliferation of pars intermedia (PI) melanotropes due to hyperplasia and adenoma formation.
  • This results in considerably reduced dopamine (DA) concentrations and tyrosine hydroxylase (TH) immunoreactivity in PI tissue.
  • Previous observations have shown that treatment with pergolide, a dopamine receptor agonist, significantly improves the clinical condition of horses affected by PPID.

Hypothesis

  • Based on the above-observed clinical improvement, the authors hypothesized that treating PPID-affected horses with pergolide could result in higher dopamine and tyrosine hydroxylase levels, compared to untreated PPID-affected horses.

Experiment

  • To test their hypothesis, the researchers removed the pituitary glands from 18 horses, which included untreated and treated PPID-affected horses, as well as horses without signs of PPID.
  • The treated horses received a daily, oral dose of pergolide for 6 months.
  • DA concentrations and TH expression levels were then determined from the collected PI tissues, with the aid of high performance liquid chromatography with electrochemical detection and Western blot analyses, respectively.

Results

  • The results demonstrated that DA and TH levels were lowest in the PI tissues collected from untreated horses with PPID.
  • In contrast, horses that were treated with pergolide showed DA and TH levels similar to those observed in aged horses without PPID symptoms.

Conclusion

  • These findings empirically support the initial hypothesis, showing that pergolide treatment can restore DA and TH levels in PPID-affected horses.
  • Furthermore, the authors suggest that equine PPID could serve as a potential animal model for studying human neurodegenerative disorders linked to dopaminergic neurodegeneration.

Cite This Article

APA
Fortin JS, Benskey MJ, Lookingland KJ, Patterson JS, Howey EB, Goudreau JL, Schott HC. (2020). Restoring pars intermedia dopamine concentrations and tyrosine hydroxylase expression levels with pergolide: evidence from horses with pituitary pars intermedia dysfunction. BMC Vet Res, 16(1), 356. https://doi.org/10.1186/s12917-020-02565-3

Publication

BMC veterinary research
ISSN: 1746-6148
NlmUniqueID: 101249759
Country: England
Language: English
Volume: 16
Issue: 1
Pages: 356
PII: 356

Researcher Affiliations

Fortin, Jessica S
  • Department of Pathobiology and Diagnostic Investigation, College of Veterinary Medicine, Michigan State University, 784 Wilson Road, East Lansing, 48824, MI, USA. fortinj1@msu.edu.
Benskey, Matthew J
  • Department of Pharmacology and Toxicology, Neuroscience Program, College of Veterinary Medicine, Michigan State University, East Lansing, MI, USA.
Lookingland, Keith J
  • Department of Pharmacology and Toxicology, Neuroscience Program, College of Veterinary Medicine, Michigan State University, East Lansing, MI, USA.
Patterson, Jon S
  • Department of Pathobiology and Diagnostic Investigation, College of Veterinary Medicine, Michigan State University, 784 Wilson Road, East Lansing, 48824, MI, USA.
Howey, Erin B
  • Department of Pathobiology and Diagnostic Investigation, College of Veterinary Medicine, Michigan State University, 784 Wilson Road, East Lansing, 48824, MI, USA.
Goudreau, John L
  • Department of Pharmacology and Toxicology, Neuroscience Program, College of Veterinary Medicine, Michigan State University, East Lansing, MI, USA.
  • Neurology and Ophthalmology, College of Osteopathic Medicine, Michigan State University, East Lansing, MI, USA.
Schott, Harold C
  • Department of Large Animal Clinical Sciences, College of Veterinary Medicine, Michigan State University, 784 Wilson Road, East Lansing, MI, 48824, USA. schott@msu.edu.

MeSH Terms

  • Aging
  • Animals
  • Dopamine / metabolism
  • Dopamine Agonists / therapeutic use
  • Horse Diseases / drug therapy
  • Horses
  • Pergolide / therapeutic use
  • Pituitary Diseases / drug therapy
  • Pituitary Diseases / veterinary
  • Pituitary Gland, Intermediate / drug effects
  • Pituitary Gland, Intermediate / pathology
  • Tyrosine 3-Monooxygenase / metabolism

Conflict of Interest Statement

The authors declare that they have no competing interests.

References

This article includes 57 references
  1. McFarlane D, Dybdal N, Donaldson MT, Miller L, Cribb AE. Nitration and increased alpha-synuclein expression associated with dopaminergic neurodegeneration in equine pituitary pars intermedia dysfunction.. J Neuroendocrinol 2005 Feb;17(2):73-80.
    doi: 10.1111/j.1365-2826.2005.01277.xpubmed: 15796757google scholar: lookup
  2. Brosnahan MM, Paradis MR. Demographic and clinical characteristics of geriatric horses: 467 cases (1989-1999).. J Am Vet Med Assoc 2003 Jul 1;223(1):93-8.
    doi: 10.2460/javma.2003.223.93pubmed: 12839071google scholar: lookup
  3. Miller MA, Pardo ID, Jackson LP, Moore GE, Sojka JE. Correlation of pituitary histomorphometry with adrenocorticotrophic hormone response to domperidone administration in the diagnosis of equine pituitary pars intermedia dysfunction.. Vet Pathol 2008 Jan;45(1):26-38.
    doi: 10.1354/vp.45-1-26pubmed: 18192571google scholar: lookup
  4. Schott HC 2nd. Pituitary pars intermedia dysfunction: equine Cushing's disease.. Vet Clin North Am Equine Pract 2002 Aug;18(2):237-70.
    pubmed: 15635907doi: 10.1016/s0749-0739(02)00018-4google scholar: lookup
  5. Innerå M, Petersen AD, Desjardins DR, Steficek BA, Rosser EJ Jr, Schott HC 2nd. Comparison of hair follicle histology between horses with pituitary pars intermedia dysfunction and excessive hair growth and normal aged horses.. Vet Dermatol 2013 Feb;24(1):212-7.e46-7.
    pubmed: 23331700doi: 10.1111/j.1365-3164.2012.01080.xgoogle scholar: lookup
  6. van der Kolk JH, Kalsbeek HC, van Garderen E, Wensing T, Breukink HJ. Equine pituitary neoplasia: a clinical report of 21 cases (1990-1992).. Vet Rec 1993 Dec 11;133(24):594-7.
    pubmed: 8116170
  7. Hillyer MH, Taylor FGRT, Mair TS, Murphy D, Watson TDG, Love S. Diagnosis of hyperadrenocorticism in the horse. Equine Vet Edu 1992;4:131–4.
    doi: 10.1111/j.2042-3292.1992.tb01595.xgoogle scholar: lookup
  8. Couëtil L, Paradis MR, Knoll J. Plasma adrenocorticotropin concentration in healthy horses and in horses with clinical signs of hyperadrenocorticism.. J Vet Intern Med 1996 Jan-Feb;10(1):1-6.
    doi: 10.1111/j.1939-1676.1996.tb02016.xpubmed: 8965262google scholar: lookup
  9. Heinrichs M, Baumgärtner W, Capen CC. Immunocytochemical demonstration of proopiomelanocortin-derived peptides in pituitary adenomas of the pars intermedia in horses.. Vet Pathol 1990 Nov;27(6):419-25.
    doi: 10.1177/030098589902700606pubmed: 2177580google scholar: lookup
  10. Spelta CW. Equine pituitary pars intermedia dysfunction: current perspectives on diagnosis and management.. Vet Med (Auckl) 2015;6:293-300.
    pmc: PMC6067528pubmed: 30101114doi: 10.2147/vmrr.s74191google scholar: lookup
  11. Kemppainen RJ, Peterson ME. Regulation of alpha-melanocyte-stimulating hormone secretion from the pars intermedia of domestic cats.. Am J Vet Res 1999 Feb;60(2):245-9.
    pubmed: 10048560
  12. Kemppainen RJ, Zerbe CA, Sartin JL. Regulation and secretion of proopiomelanocortin peptides from isolated perifused dog pituitary pars intermedia cells.. Endocrinology 1989 May;124(5):2208-17.
    doi: 10.1210/endo-124-5-2208pubmed: 2539971google scholar: lookup
  13. Dybdal NO, Hargreaves KM, Madigan JE, Gribble DH, Kennedy PC, Stabenfeldt GH. Diagnostic testing for pituitary pars intermedia dysfunction in horses.. J Am Vet Med Assoc 1994 Feb 15;204(4):627-32.
    pubmed: 8163420
  14. Morgan RA, Keen JA, Homer N, Nixon M, McKinnon-Garvin AM, Moses-Williams JA, Davis SR, Hadoke PWF, Walker BR. Dysregulation of Cortisol Metabolism in Equine Pituitary Pars Intermedia Dysfunction.. Endocrinology 2018 Nov 1;159(11):3791-3800.
    doi: 10.1210/en.2018-00726pmc: PMC6202856pubmed: 30289445google scholar: lookup
  15. Luppi PH, Sakai K, Salvert D, Berod A, Jouvet M. Periventricular dopaminergic neurons terminating in the neuro-intermediate lobe of the cat hypophysis.. J Comp Neurol 1986 Feb 8;244(2):204-12.
    doi: 10.1002/cne.902440207pubmed: 2869071google scholar: lookup
  16. Goudreau JL, Falls WM, Lookingland KJ, Moore KE. Periventricular-hypophysial dopaminergic neurons innervate the intermediate but not the neural lobe of the rat pituitary gland.. Neuroendocrinology 1995 Aug;62(2):147-54.
    doi: 10.1159/000126999pubmed: 8584114google scholar: lookup
  17. McFarlane D, Cribb AE. Systemic and pituitary pars intermedia antioxidant capacity associated with pars intermedia oxidative stress and dysfunction in horses.. Am J Vet Res 2005 Dec;66(12):2065-72.
    doi: 10.2460/ajvr.2005.66.2065pubmed: 16379648google scholar: lookup
  18. Millington WR, Dybdal NO, Dawson R Jr, Manzini C, Mueller GP. Equine Cushing's disease: differential regulation of beta-endorphin processing in tumors of the intermediate pituitary.. Endocrinology 1988 Sep;123(3):1598-604.
    doi: 10.1210/endo-123-3-1598pubmed: 2456916google scholar: lookup
  19. Saiardi A, Borrelli E. Absence of dopaminergic control on melanotrophs leads to Cushing's-like syndrome in mice.. Mol Endocrinol 1998 Aug;12(8):1133-9.
    pubmed: 9717839doi: 10.1210/mend.12.8.0144google scholar: lookup
  20. Calabrese V, Bates TE, Stella AM. NO synthase and NO-dependent signal pathways in brain aging and neurodegenerative disorders: the role of oxidant/antioxidant balance.. Neurochem Res 2000 Oct;25(9-10):1315-41.
    doi: 10.1023/A:1007604414773pubmed: 11059804google scholar: lookup
  21. Gilgun-Sherki Y, Melamed E, Offen D. Oxidative stress induced-neurodegenerative diseases: the need for antioxidants that penetrate the blood brain barrier.. Neuropharmacology 2001 Jun;40(8):959-75.
    doi: 10.1016/S0028-3908(01)00019-3pubmed: 11406187google scholar: lookup
  22. Luo Y, Roth GS. The roles of dopamine oxidative stress and dopamine receptor signaling in aging and age-related neurodegeneration.. Antioxid Redox Signal 2000 Fall;2(3):449-60.
    doi: 10.1089/15230860050192224pubmed: 11229358google scholar: lookup
  23. Finkel T, Holbrook NJ. Oxidants, oxidative stress and the biology of ageing.. Nature 2000 Nov 9;408(6809):239-47.
    doi: 10.1038/35041687pubmed: 11089981google scholar: lookup
  24. Lee PC, Bordelon Y, Bronstein J, Sinsheimer JS, Farrer M, Ritz B. Head injury, α-synuclein genetic variability and Parkinson's disease.. Eur J Neurol 2015 May;22(5):874-8.
    doi: 10.1111/ene.12585pmc: PMC4390403pubmed: 25370538google scholar: lookup
  25. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos ES, Chandrasekharappa S, Athanassiadou A, Papapetropoulos T, Johnson WG, Lazzarini AM, Duvoisin RC, Di Iorio G, Golbe LI, Nussbaum RL. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease.. Science 1997 Jun 27;276(5321):2045-7.
    doi: 10.1126/science.276.5321.2045pubmed: 9197268google scholar: lookup
  26. Saha AR, Ninkina NN, Hanger DP, Anderton BH, Davies AM, Buchman VL. Induction of neuronal death by alpha-synuclein.. Eur J Neurosci 2000 Aug;12(8):3073-7.
    doi: 10.1046/j.1460-9568.2000.00210.xpubmed: 10971650google scholar: lookup
  27. Giasson BI, Duda JE, Murray IV, Chen Q, Souza JM, Hurtig HI, Ischiropoulos H, Trojanowski JQ, Lee VM. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions.. Science 2000 Nov 3;290(5493):985-9.
    doi: 10.1126/science.290.5493.985pubmed: 11062131google scholar: lookup
  28. Nagatsu T, Nakashima A, Ichinose H, Kobayashi K. Human tyrosine hydroxylase in Parkinson's disease and in related disorders.. J Neural Transm (Vienna) 2019 Apr;126(4):397-409.
    doi: 10.1007/s00702-018-1903-3pubmed: 29995172google scholar: lookup
  29. Silva MA, Mattern C, Häcker R, Tomaz C, Huston JP, Schwarting RK. Increased neostriatal dopamine activity after intraperitoneal or intranasal administration of L-DOPA: on the role of benserazide pretreatment.. Synapse 1997 Dec;27(4):294-302.
    doi: 10.1002/(SICI)1098-2396(199712)27:4<294::AID-SYN3>3.0.CO;2-7pubmed: 9372552google scholar: lookup
  30. Sweet RD, McDowell FH. Five years' treatment of Parkinson's disease with levodopa. Therapeutic results and survival of 100 patients.. Ann Intern Med 1975 Oct;83(4):456-63.
    doi: 10.7326/0003-4819-83-4-456pubmed: 1166978google scholar: lookup
  31. Lesser RP, Fahn S, Snider SR, Cote LJ, Isgreen WP, Barrett RE. Analysis of the clinical problems in parkinsonism and the complications of long-term levodopa therapy.. Neurology 1979 Sep;29(9 Pt 1):1253-60.
    doi: 10.1212/WNL.29.9_Part_1.1253pubmed: 573405google scholar: lookup
  32. Block G, Liss C, Reines S, Irr J, Nibbelink D. Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. A multicenter 5-year study. The CR First Study Group.. Eur Neurol 1997;37(1):23-7.
    doi: 10.1159/000117399pubmed: 9018028google scholar: lookup
  33. Melamed E, Offen D, Shirvan A, Djaldetti R, Barzilai A, Ziv I. Levodopa toxicity and apoptosis.. Ann Neurol 1998 Sep;44(3 Suppl 1):S149-54.
    doi: 10.1002/ana.410440722pubmed: 9749587google scholar: lookup
  34. Halliwell B. Reactive oxygen species and the central nervous system.. J Neurochem 1992 Nov;59(5):1609-23.
    doi: 10.1111/j.1471-4159.1992.tb10990.xpubmed: 1402908google scholar: lookup
  35. Rajput AH, Fenton Me, Birdi S, Macaulay R. Is levodopa toxic to human substantia nigra?. Mov Disord 1997 Sep;12(5):634-8.
    doi: 10.1002/mds.870120503pubmed: 9380042google scholar: lookup
  36. Quinn N. Drug treatment of Parkinson's disease.. BMJ 1995 Mar 4;310(6979):575-9.
    doi: 10.1136/bmj.310.6979.575pmc: PMC2548944pubmed: 7888935google scholar: lookup
  37. Uitti RJ, Ahlskog JE. Comparative Review of Dopamine Receptor Agonists in Parkinson's Disease.. CNS Drugs 1996 May;5(5):369-88.
    doi: 10.2165/00023210-199605050-00006pubmed: 26071049google scholar: lookup
  38. Fischer PA. Treatment strategies in Parkinson's disease after a quarter century experiences with L-DOPA therapy.. J Neural Transm Suppl 1995;46:381-9.
    pubmed: 8821073
  39. Oertel WH, Quinn NP. Parkinson's disease: drug therapy.. Baillieres Clin Neurol 1997 Apr;6(1):89-108.
    pubmed: 9426870
  40. Rascol O, Brooks DJ, Brunt ER, Korczyn AD, Poewe WH, Stocchi F. Ropinirole in the treatment of early Parkinson's disease: a 6-month interim report of a 5-year levodopa-controlled study. 056 Study Group.. Mov Disord 1998 Jan;13(1):39-45.
    doi: 10.1002/mds.870130111pubmed: 9452324google scholar: lookup
  41. Boas JWP J, Dupont E, Mikkelsen B, Wermuth L. The levodopa dose-sparing capacity of pergolide compared with that of bromocriptine in an open‐label, crossover study. Eur J Neurol 1996;3:44–9.
    doi: 10.1111/j.1468-1331.1996.tb00188.xgoogle scholar: lookup
  42. Pezzoli G, Martignoni E, Pacchetti C, Angeleri VA, Lamberti P, Muratorio A, Bonuccelli U, De Mari M, Foschi N, Cossutta E. Pergolide compared with bromocriptine in Parkinson's disease: a multicenter, crossover, controlled study.. Mov Disord 1994 Jul;9(4):431-6.
    doi: 10.1002/mds.870090409pubmed: 7969210google scholar: lookup
  43. Bonnet AM, Serre I, Marconi R, Agid Y, Dubois B. A "combined" levodopa test as a useful method for evaluating the efficacy of dopamine agonists: application to pergolide and bromocriptine.. Mov Disord 1995 Sep;10(5):668-71.
    doi: 10.1002/mds.870100522pubmed: 8552122google scholar: lookup
  44. Donaldson MT, LaMonte BH, Morresey P, Smith G, Beech J. Treatment with pergolide or cyproheptadine of pituitary pars intermedia dysfunction (equine Cushing's disease).. J Vet Intern Med 2002 Nov-Dec;16(6):742-6.
    pubmed: 12465775doi: 10.1892/0891-6640(2002)016<0742:twpoco>2.3.co;2google scholar: lookup
  45. Wang Y, Sung CC, Chung KK. Novel enhancement mechanism of tyrosine hydroxylase enzymatic activity by nitric oxide through S-nitrosylation.. Sci Rep 2017 Mar 13;7:44154.
    doi: 10.1038/srep44154pmc: PMC5347018pubmed: 28287127google scholar: lookup
  46. McFarlane D. Equine pituitary pars intermedia dysfunction.. Vet Clin North Am Equine Pract 2011 Apr;27(1):93-113.
    doi: 10.1016/j.cveq.2010.12.007pubmed: 21392656google scholar: lookup
  47. McFarlane D, Banse H, Knych HK, Maxwell LK. Pharmacokinetic and pharmacodynamic properties of pergolide mesylate following long-term administration to horses with pituitary pars intermedia dysfunction.. J Vet Pharmacol Ther 2017 Apr;40(2):158-164.
    doi: 10.1111/jvp.12339pubmed: 27301465google scholar: lookup
  48. Durham AE. Therapeutics for Equine Endocrine Disorders.. Vet Clin North Am Equine Pract 2017 Apr;33(1):127-139.
    doi: 10.1016/j.cveq.2016.11.003pubmed: 28190613google scholar: lookup
  49. Gehlert DR, Bishop JF, Schafer MP, Chronwall BM. Rat intermediate lobe in culture: dopaminergic regulation of POMC biosynthesis and cell proliferation.. Peptides 1988;9 Suppl 1:161-8.
    doi: 10.1016/0196-9781(88)90240-9pubmed: 2908811google scholar: lookup
  50. McFarlane D. Pathophysiology and clinical features of pituitary pars intermedia dysfunction. Veterinary Education 2014;26:592–8.
    doi: 10.1111/eve.12237google scholar: lookup
  51. Melrose PA, Walker RF, Douglas RH. Dopamine in the cerebrospinal fluid of prepubertal and adult horses.. Brain Behav Evol 1990;35(2):98-106.
    doi: 10.1159/000115859pubmed: 2112971google scholar: lookup
  52. Fujisawa H, Okuno S. Regulatory mechanism of tyrosine hydroxylase activity.. Biochem Biophys Res Commun 2005 Dec 9;338(1):271-6.
    doi: 10.1016/j.bbrc.2005.07.183pubmed: 16105651google scholar: lookup
  53. Booij J, de Bruin K, de Win MM, Lavini C, den Heeten GJ, Habraken JB. Imaging of striatal dopamine transporters in rat brain with single pinhole SPECT and co-aligned MRI is highly reproducible.. Nucl Med Biol 2003 Aug;30(6):643-9.
    doi: 10.1016/S0969-8051(03)00046-5pubmed: 12900290google scholar: lookup
  54. Kordower JH, Olanow CW, Dodiya HB, Chu Y, Beach TG, Adler CH, Halliday GM, Bartus RT. Disease duration and the integrity of the nigrostriatal system in Parkinson's disease.. Brain 2013 Aug;136(Pt 8):2419-31.
    doi: 10.1093/brain/awt192pmc: PMC3722357pubmed: 23884810google scholar: lookup
  55. Bankiewicz KS, Eberling JL, Kohutnicka M, Jagust W, Pivirotto P, Bringas J, Cunningham J, Budinger TF, Harvey-White J. Convection-enhanced delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach.. Exp Neurol 2000 Jul;164(1):2-14.
    doi: 10.1006/exnr.2000.7408pubmed: 10877910google scholar: lookup
  56. Pardridge WM. Tyrosine hydroxylase replacement in experimental Parkinson's disease with transvascular gene therapy.. NeuroRx 2005 Jan;2(1):129-38.
    doi: 10.1602/neurorx.2.1.129pmc: PMC539333pubmed: 15717064google scholar: lookup
  57. Schott IIHC, Patterson JS, Howey EB, Benskey MJ, Goudreau JL, Lookingland KJ. Dopamine and tyrosine hydroxylase concentrations in pars intermedia tissue of horses with pituitary pars intermedia dysfunction with and without pergolide treatment. J Vet Intern Med 2012;26(3):736.

Citations

This article has been cited 5 times.
  1. Kirkwood NC, Hughes KJ, Stewart AJ. Pituitary Pars Intermedia Dysfunction (PPID) in Horses. Vet Sci 2022 Oct 10;9(10).
    doi: 10.3390/vetsci9100556pubmed: 36288169google scholar: lookup
  2. Fortin JS, Hetak AA, Duggan KE, Burglass CM, Penticoff HB, Schott HC 2nd. Equine pituitary pars intermedia dysfunction: a spontaneous model of synucleinopathy. Sci Rep 2021 Aug 6;11(1):16036.
    doi: 10.1038/s41598-021-95396-7pubmed: 34362943google scholar: lookup
  3. Kelly MA, Anderson K, Saleh MN, Ramos RAN, Valeris-Chacin RJ, Budke CM, Verocai GG. High seroprevalence of selected vector-borne pathogens in dogs from Saipan, Northern Mariana Islands. Parasit Vectors 2025 Feb 24;18(1):75.
    doi: 10.1186/s13071-025-06705-2pubmed: 39994743google scholar: lookup
  4. Wang W, Gibson J, Horsman S, Mikkelsen D, Bertin FR. Characterization and comparison of fecal microbiota in horses with pituitary pars intermedia dysfunction and age-matched controls. J Vet Intern Med 2025 Jan-Feb;39(1):e17288.
    doi: 10.1111/jvim.17288pubmed: 39853825google scholar: lookup
  5. Miller SJ, Darji RY, Walaieh S, Lewis JA, Logan R. Senolytic and senomorphic secondary metabolites as therapeutic agents in Drosophila melanogaster models of Parkinson's disease. Front Neurol 2023;14:1271941.
    doi: 10.3389/fneur.2023.1271941pubmed: 37840914google scholar: lookup
Subscribe to our newsletter
Join 99,357 horse owners like you who receive our email updates on horse health and nutrition.